Zim Laboratories Ltd — earnings calls
1 quarter summarised from transcripts filed with the exchange, every statement cited. Newest first.
Zim Laboratories reported full year FY26 total operating income of approximately INR 3,744 million, broadly flat versus FY25, which management attributed to an estimated INR 20-25 crore revenue impact from MENA geopolitical disruption and continued EU GMP related constraints on the regulated pipeline. The company underwent an EU GMP re-inspection by German and Portuguese authorities from May 4-7, 2026, and management said the CAPA implementation is substantially complete with a positive outcome expected. Q4 FY26 EBITDA margin was approximately 12.7% and full year PAT stood at INR 58 million, with exports contributing approximately 82% of quarterly operating income.